Surgery for patients with newly diagnosed advanced ovarian cancer: which patient, when and extent?

Florine A Eggink, Corine M Koopmans, Hans W Nijman

Research output: Contribution to journalReview articleAcademicpeer-review

4 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Cytoreduction to no residual disease is the mainstay of primary treatment for advanced epithelial ovarian cancer (AdvEOC). This review addresses recent insights on optimal patient selection, timing, and extent of surgery, intended to optimize cytoreduction in patients with AdvEOC.

RECENT FINDINGS: Clinical guidelines recommend primary cytoreductive surgery (PCS) for AdvEOC patients with a high likelihood of achieving complete cytoreduction with acceptable morbidity. In line with this, preoperative prediction markers such as cancer antigen-125, histologic and genomic factors, innovative imaging modalities, and the performance of a diagnostic laparoscopy have been suggested to improve clinical decision-making with regard to optimal timing of cytoreductive surgery. To determine whether these strategies should be incorporated into clinical practice validation in randomized clinical trials is essential.

SUMMARY: The past decade has seen a paradigm shift in the number of AvdEOC patients that are being treated with upfront neoadjuvant chemotherapy instead of PCS. However, although neoadjuvant chemotherapy may reduce morbidity at the time of interval cytoreductive surgery, no favorable impact on survival has been demonstrated and it may induce resistance to chemotherapy. Therefore, optimizing patient selection for PCS is crucial. Furthermore, surgical innovations in patients diagnosed with AvdEOC should focus on improving survival outcomes.

Original languageEnglish
Pages (from-to)351-358
Number of pages8
JournalCurrent opinion in oncology
Volume29
Issue number5
DOIs
Publication statusPublished - Sep-2017

Keywords

  • advanced epithelial ovarian cancer
  • cytoreduction
  • neoadjuvant chemotherapy
  • patient selection
  • survival
  • PRIMARY CYTOREDUCTIVE SURGERY
  • GROSS RESIDUAL DISEASE
  • NEOADJUVANT CHEMOTHERAPY
  • PRIMARY DEBULKING
  • CARCINOMA
  • METAANALYSIS
  • SURVIVAL
  • PREDICT
  • IMPACT
  • TRIAL

Cite this